NCT02167854View on ClinicalTrials.gov

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 16, 2014

Primary Completion Date

July 7, 2021

Study Completion Date

July 7, 2021

Conditions
Breast Cancer
Interventions
DRUG

BYL719

DRUG

LJM716

DRUG

TRASTUZUMAB

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memoral Sloan Kettering Westchester, Harrison

11570

Memorial Sloan Kettering Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02167854 - Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer | Biotech Hunter | Biotech Hunter